53.00
-2.50
(-4.50%)
As of 8:10:55 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 12 | 12 | 14 | 15 |
| Avg. Estimate | 9.42B | 10.18B | 39.84B | 42.22B |
| Low Estimate | 9.28B | 10.06B | 39.41B | 40.89B |
| High Estimate | 9.57B | 10.25B | 40.15B | 43.53B |
| Year Ago Sales | 8.95B | 9.71B | 37.88B | 39.84B |
| Sales Growth (year/est) | 5.21% | 4.80% | 5.18% | 5.96% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| UFH.F | -- | -- | -- | -- |
| S&P 500 | 6.55% | 6.50% | 9.70% | 14.29% |
Upgrades & Downgrades
| Maintains | Piper Sandler: Overweight to Overweight | 2/18/2025 |
| Maintains | UBS: Buy to Buy | 2/14/2025 |
| Maintains | Truist Securities: Buy to Buy | 2/14/2025 |
| Maintains | Barclays: Overweight to Overweight | 2/14/2025 |
| Maintains | Morgan Stanley: Overweight to Overweight | 1/21/2025 |
| Maintains | Truist Securities: Buy to Buy | 1/16/2025 |